![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Gonane Triamcinolone](https://www.pharmacompass.com/image/flap/gonane-triamcinolone-desktop-headergif-14577.gif)
![Gonane Triamcinolone](https://www.pharmacompass.com/image/flap/gonane-triamcinolone-mobile-headergif-15972.gif)
Active Filter(s):
Details:
SAR439483 (ATSN-101) is a novel GUCY2D modulator which is currently being evaluated in phase 1/2 clinical development for the treatment of GUCY2D-associated leber congenital amaurosis (LCA1).
Lead Product(s): ATSN-101,Prednisone,Triamcinolone
Therapeutic Area: Rare Diseases and Disorders Product Name: SAR439483
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024